Cellective Therapeutics - Ownership and Business Overview

Life ScienceCompany

Cellective Therapeutics Ownership

Who owns Cellective Therapeutics?

Cellective Therapeutics is owned by MedImmune. It was acquired on September 14, 2005.

Cellective Therapeutics Business Overview

Where is Cellective Therapeutics headquartered?

Cellective Therapeutics is headquartered in Gaithersburg, Maryland.

What sector is Cellective Therapeutics in?

Cellective Therapeutics is a life science company.

When was Cellective Therapeutics founded?

Cellective Therapeutics was founded in 2003.

Life Science M&A Summary in 2005

Out of 60 sectors in the Mergr database, life science ranked 13 in number of deals in 2005. The largest life science acquisition in 2005 was Ivax - which was acquired by Teva Pharmaceutical Industries for $7.4B.

Join Mergr to view all 78 acquisitions of life science companies in 2005, including 18 acquisitions by private equity firms, and 60 by strategics.

Cellective Therapeutics, Inc.

35 West Watkins Mill Road, Suite 100,
Gaithersburg, Maryland 20878
United States,
301-977-7042
www.medimmune.com

Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, Crohn?s disease and rheumatoid arthritis. The Company was founded in 2003 by Dr. Tom Tedder, Chairman of the Department of Immunology at Duke University, and based on technology licensed from Duke University and the Dana Farber Cancer Institute. Cellective was acquired by MedImmune in September of 2005.


 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.